THE STRATEGIES FOR PRIMARY PREVENTION OF PROSTATE CANCER – EVERYDAY PRACTICE, UNREALISTIC FICTION OR NEAR FUTURE?
Authors:
V. Vít
Authors‘ workplace:
Urologická klinika FN Brno
Published in:
Urol List 2011; 9(2): 7-11
Overview
Prostate cancer stands in the spotlight of urologists in all western countries. Due to its high incidence and prevalence prostate cancer poses a threat for a large population of men as well as a significant burden for heath care systems. The question of prostate cancer prevention is therefore a critical one. Development of strategies for prostate cancer prevention requires a thorough knowledge of all the factors responsible for its etiology. The author in his article discusses the individual etiologic factors (age, hormonal environment, ethnic and geographical aspects, genetic factors, dietary factors, obesity, chronic prostate inflammation) as well as the strategies, which could alter these conditions in terms of prostate cancer prevention. He evaluates the methods of medicamentous prevention and the role of dietary supplements.
Key words:
prostate cancer, etiologic factors, primary prevention
Sources
1. UZIS, 2011 – www.svod.cz
2. Gronberg H: Prostate cancer epidemiology. Lancet 2003, 361: 859–864.
3. Steers WU. 5a1alpha-reductase aktivity in the prostate cancer. Urology 2001, 58 (6 Suppl 1): 17–24.
4. Whittemore AS, Kolonel LN et al. Prostate cancer in relation to diet, physical aktivity, and body size in blacks, whites, and Asians in the United States and Canada. J Nat Cancer Inst 1995; 87(9): 652–661
5. Quinn M, Babb P. Patterns and trends in prostate cancer incidence,survival, prevalence and mortality. Part I: international comparisons. BJU Int 2002; 90(2): 162–173.
6. Eeles RA, Dearnaley DP, Ardern-Jones A et al. Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. Br J Urol 1997; 79 (Suppl 1): 8–14.
7. Carter BS, Bova GS, Beaty TH et al. Hereditary prostate cancer epidemiologic and clinical features. J Urol 1993; 150(3): 797–802.
8. Bostwick DG, Burke HB, Djakiew D et al. Human prostate cancer risk factors. Cancer 2004; 101(10 Suppl): 2371–2490.
9. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002; 60(1): 78–83.
10. Samanta M, Harkins L, Klemm K et al. High prevalence of human cytomegalovirus in prostatic intraepitelial neoplasia and prostatic carcinoma. J Urol 2003; 170(3): 998–1002.
11. Zambrano A, Kalantari M, Simoneau A et al. Detection of human polyomaviruses and papilomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infection. Prostate 2002; 53(4): 263–276.
12. Steers WU. 5a1alpha-reductase aktivity in the prostate cancer. Urology 2001; 58 (6 Suppl 1): 17–24.
13. Andriole G, Bruchovsky N, Chung LW et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatmen of benign prostatic hyperplasia. J Urol 2004; 172 (4 Pt 1): 1399–1403.
14. Rittnaster RS. Finasteride. N Engl J Med 1994; 330(2): 120–125.
15. Keller J. Effect of finasteride, a 5alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab 1990; 71(6): 1552–1555.
16. Mc Donnel JD, Wilson JD, Georgie FW et al. Finasteride.an inhibitor of 5alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74(3): 505–508.
17. Thompson IM, Goodman PJ, Tanger CM et al. The influence of finasteride on the development of prostatě cancer. N Engl J Med 2003; 349(3): 215–224.
18. Wessells H, Roy J, Bannow J et al. Incidence and Severity of sexual averse experiences in finasterid and placebo-treated men with benign prostatic hyperplasia. Urology 2003; 61(3): 579–584.
19. McConnell JD, Roehrborn CG, Baptista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349(25): 2387–2398.
20. Giovannucci E. A review of epidemiologic studies of tomatoes, lycopene, and prostate cancer. Exp Biol Med 2002; 227(10): 852–859.
21. Klein E, Thompson I. Update on chemoprevention of prostate cancer. Current Opinion in Urology 2004; 14(3): 143–149.
22. Clark LC et al. Effect of selenium supplementation for cancer prevention with carcinoma of the skin: a randomized controlled trial. Journal of the American Medical Association 1996; 276: 1957–1963.
23. Brooks JD, Meter EJ, Chan DW et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 2001; 166(6): 2034–2038.
24. Thompson TA, Wilding G. Androgen Antagonist Activity by the Antioxidant Moiety of Vitamin E, 2,2,5,7,8-Pentamethyl-6-chromanol in Human Prostate Carcinoma Cells. Mol Cancer Ther 2003; 2: 797–803.
25. Rodriguez C, Jacobs EJ, Mondul AM et al. Vitamin E Supplements and Risk of Prostate Cancer in U.S. Men. Cancer Epidemiol Biomarkers Prev 2004(8); 13: 378–382.
26. Yu L, Blackburn GL, Zhou JR. Genistein and daidzein downregulate prostate androgen-regulated transcript-1 (PART-1) gene expression induced by dihydrotestosterone in human prostate LNCaP cancer cells. J Nutr 2003; 133(2): 389.
27. Adhami VM, Ahmad N, Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J Nutr 2003; 133 (Suppl 7): 2417S–2424S.
28. Schwartz GG. Vitamin D and the epidemiology of prostate cancer. Semin Dial 2005; 18(4): 276–289.
29. Wolk A. Diet, lifestyle and risk of prostate cancer. Acta Oncol 2005; 44(3): 277–281.
30. Andrews J, Djakiew D, Krygler S et al. Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. Cancer Chemother Pharmacol 2000; 50(4): 277.
31. Jacobs EJ, Rodriguez C, Mondul AM et al. A large kohort study of Aspirin and other nonsteroidal antiinflammatory drugs and prostate cancer incidence. Journal Of The National Cancer Institute 2005; 97(13): 975–980.
32. Chan JM, Feraco A, Shuman M et al. The epidemiology of prostate cancer with a focus on nonsteroidal anti-inflammatory drugs. Hematol Oncol Clin North Am 2006; 20(4): 797.
Labels
Paediatric urologist UrologyArticle was published in
Urological Journal
2011 Issue 2
Most read in this issue
- A SUMMARY OF NEW TECHNOLOGIES FOR PROSTATE CANCER (ROBOT, LAP, BRACHY, CRYO, CYBERKNIFE)
- EAU GUIDELINES ON PROSTATE CANCER - PART 1: SCREENING, DIAGNOSIS, AND TREATMENT OF CLINICALLY LOCALISED DISEASE
- SCREENING OF PROSTATE CANCER
- EAU GUIDELINES ON PROSTATE CANCERPART 2: TREATMENT OF ADVANCED, RELAPSING, AND CASTRATION-RESISTANT PROSTATE CANCER